403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Genente’h’s approval in breast cancer among nine key value-driving biopharma catalysts in Q4 2026, reveals GlobalData
(MENAFN- Cision) Several keenly anticipated approval decisions governing critical catalysts that can shape biopharma sentiment are expected in Q4 2024, alongside key clinical trial milestones that could influence the industry's landscape. One of them is Genen’ech’s’Roche’s giredestrant, which faces two regulatory decisions in breast cancer; one is an approval decision by November 30, for early-stage ER+/HER2- breast cancer and another by December 18 for giredestrant plus everolimus in patients with advanced or metastatic ER+/HER2-/ESR1-mutated (ESR1m) disease following endocrine therapy, says GlobalData, a leading intelligence and productivity platform.
The two anticipated regulatory decisions for giredestrant could broaden the asset’s positioning in the evolving oral selective estrogen receptor degrader (SERD) landscape, potentially validating its role in ESR1-mutated advanced disease while extending the class into the substantially larger early-stage adjuvant setting,
GlobalDa’a’s Catalyst Monitor: Q4 2026 Outlook, which includes insights on a total of 26 significant events that are expected to occur in Q4 2026, reveals a positive outlook for another significant approval decision: Summit Therapeu’ics’ ivonescimab.
Irena Maragkou, Senior Healthcare Researcher at GlobalData, comm“nts: “Experts anticipate that, if approved, ivonescimab could establish dual VEGF/PD-1 blockade as a new treatment approach for second-line EGFR-mutated non-small cell lung cancer (NSCLC), addressing an area of unmet need while potentially offering greater convenience and lower toxicity than combinations of separate checkpoint and VEGF inhibitors. Its commercial trajectory, however, could hinge on whether the efficacy seen in HARMONi, particularly the overall survival benefit, is compelling enough to drive adoption and differentiate ivonescimab from established checkpoint-based treatment ”ptions.”
Ivonescimab is expected to generate $1 billion in sales in 2032, as per GlobalData estimates. Some of the other catalyst events covered in the report include those related to Sun Pharmaceutical Industries, Bayer, Agios Pharmaceuticals, Mineralys Therapeutics, Novo Nordisk and Regeneron.
Additionally, Exelixis is expecting topline data from the Phase III STELLAR-304 trial evaluating zanzalintinib plus Bristol Myers Squibb's Opdivo (nivolumab) versus Pfizer's Sutent (sunitinib), in previously untreated advanced non-clear cell renal cell carcinoma (nccRCC). The asset is a next-generation tyrosine kinase inhibitor (TKI) that has the potential to replace Cabometyx (cabozantinib) as the company’s leading TKI in RCC, with experts citing its shorter half-life and potential tolerability advantages as key differentiators.
Maragkou adds“ “Positive STELLAR-304 data could position zanzalintinib as a new first-line option in advanced nccRCC, with its shorter half-life potentially offering tolerability and combination advantages over existing tyrosine kinase inhibitors. However, the heterogeneity of nccRCC and use of sunitinib as the comparator could complicate interpretation of a positive readout, while evolving treatment practices and future generic competition may ultimately influence the ’rug’s commercial positi”ning.”
Another pivotal catalyst is NewAmsterdam Pharma's topline data from the Phase III PREVAIL cardiovascular outcomes trial of obicetrapib, which is expected in Q4 2026. The drug is an oral cholesteryl ester transfer protein (CETP) inhibitor designed to substantially reduce LDL-C.
Maragkou con“inues: “A favorable Phase III trial readout could also help overcome the ’ETP class’s history of clinical setbacks and re-establish the mechanism as a viable cardiovascular strategy. However, any disconnect between lipid lowering and cardiovascular outcomes could materially challenge’obicetrapib’s differentiation and commerc”al potential.”
Mara“kou concludes: “Looking ahead to Q4 2026, the biopharma sector is set for an event-heavy end to the year, with numerous regulatory decisions, pivotal clinical readouts and other value-driving catalysts across multiple therapeutic areas. The quarter is also expected to see a notable increase in trial completions and regulatory filings compared with Q3, which could shape development strategies, investor sentiment and the competitive outlook ”eading into 2027.”
The two anticipated regulatory decisions for giredestrant could broaden the asset’s positioning in the evolving oral selective estrogen receptor degrader (SERD) landscape, potentially validating its role in ESR1-mutated advanced disease while extending the class into the substantially larger early-stage adjuvant setting,
GlobalDa’a’s Catalyst Monitor: Q4 2026 Outlook, which includes insights on a total of 26 significant events that are expected to occur in Q4 2026, reveals a positive outlook for another significant approval decision: Summit Therapeu’ics’ ivonescimab.
Irena Maragkou, Senior Healthcare Researcher at GlobalData, comm“nts: “Experts anticipate that, if approved, ivonescimab could establish dual VEGF/PD-1 blockade as a new treatment approach for second-line EGFR-mutated non-small cell lung cancer (NSCLC), addressing an area of unmet need while potentially offering greater convenience and lower toxicity than combinations of separate checkpoint and VEGF inhibitors. Its commercial trajectory, however, could hinge on whether the efficacy seen in HARMONi, particularly the overall survival benefit, is compelling enough to drive adoption and differentiate ivonescimab from established checkpoint-based treatment ”ptions.”
Ivonescimab is expected to generate $1 billion in sales in 2032, as per GlobalData estimates. Some of the other catalyst events covered in the report include those related to Sun Pharmaceutical Industries, Bayer, Agios Pharmaceuticals, Mineralys Therapeutics, Novo Nordisk and Regeneron.
Additionally, Exelixis is expecting topline data from the Phase III STELLAR-304 trial evaluating zanzalintinib plus Bristol Myers Squibb's Opdivo (nivolumab) versus Pfizer's Sutent (sunitinib), in previously untreated advanced non-clear cell renal cell carcinoma (nccRCC). The asset is a next-generation tyrosine kinase inhibitor (TKI) that has the potential to replace Cabometyx (cabozantinib) as the company’s leading TKI in RCC, with experts citing its shorter half-life and potential tolerability advantages as key differentiators.
Maragkou adds“ “Positive STELLAR-304 data could position zanzalintinib as a new first-line option in advanced nccRCC, with its shorter half-life potentially offering tolerability and combination advantages over existing tyrosine kinase inhibitors. However, the heterogeneity of nccRCC and use of sunitinib as the comparator could complicate interpretation of a positive readout, while evolving treatment practices and future generic competition may ultimately influence the ’rug’s commercial positi”ning.”
Another pivotal catalyst is NewAmsterdam Pharma's topline data from the Phase III PREVAIL cardiovascular outcomes trial of obicetrapib, which is expected in Q4 2026. The drug is an oral cholesteryl ester transfer protein (CETP) inhibitor designed to substantially reduce LDL-C.
Maragkou con“inues: “A favorable Phase III trial readout could also help overcome the ’ETP class’s history of clinical setbacks and re-establish the mechanism as a viable cardiovascular strategy. However, any disconnect between lipid lowering and cardiovascular outcomes could materially challenge’obicetrapib’s differentiation and commerc”al potential.”
Mara“kou concludes: “Looking ahead to Q4 2026, the biopharma sector is set for an event-heavy end to the year, with numerous regulatory decisions, pivotal clinical readouts and other value-driving catalysts across multiple therapeutic areas. The quarter is also expected to see a notable increase in trial completions and regulatory filings compared with Q3, which could shape development strategies, investor sentiment and the competitive outlook ”eading into 2027.”
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment